IL15RA

IL15RA encodes the private alpha subunit of the interleukin-15 receptor, functioning primarily as a high-affinity ligand-binding chain that captures IL-15 and presents it in trans to neighboring cells or in cis on the same cell to activate downstream signaling through the shared IL-2Rβ/γc heterodimer. IL15RA binds IL-15 with ~1000-fold higher affinity than IL-2Rα binds IL-2, and its cytoplasmic domain is dispensable for mitogenic signaling; cis presentation on CD8+ T cells enhances STAT5 phosphorylation, proliferation, and cytotoxic potential (PMID:8530383, PMID:19180469). In cancer cells lacking IL-2Rβ/γc, IL15RA activates a non-canonical JAK1–STAT1/STAT2–AKT–ERK pathway promoting proliferation and survival, and in pancreatic cancer it engages a STAT3–GPX4/ACSL3 axis that confers ferroptosis resistance (PMID:24980552, PMID:39396119). Beyond immune signaling, IL15RA has cell-autonomous roles in skeletal muscle, where its loss increases mitochondrial content, cristae density, and oxidative capacity, and in bone, where it is required for normal osteoblast-driven mineralization and osteoblast–osteoclast coupling (PMID:25505029, PMID:30301784, PMID:28602725).

1. 1995 High

   Establishing that IL15RA is the high-affinity ligand-binding subunit of the IL-15 receptor — with an affinity far exceeding IL-2Rα for IL-2 — and that its cytoplasmic domain is dispensable for signaling resolved the fundamental question of how IL-15 specificity is encoded within the shared IL-2/IL-15 receptor system.

   Evidence Binding assays with spliced receptor variants, cytoplasmic domain deletion mutants, and mitogenic signaling assays in cell lines

   PMID:8530383

   Open questions at the time

   • Structural basis of the ~1000-fold affinity difference unresolved
   • Whether IL15RA has signaling-independent functions not addressed
   • Physiological cell types requiring alpha chain versus beta/gamma-only signaling not defined
2. 2009 High

   Demonstrating that IL15RA on CD8+ T cells can present IL-15 in cis — not only in trans from accessory cells — expanded the receptor's functional repertoire beyond a simple antigen-presenting-cell-to-T-cell relay and showed autonomous enhancement of T cell proliferation and cytotoxicity.

   Evidence RNA nucleofection of IL-15Rα or IL-15/IL-15Rα fusion constructs into naive CD8+ T cells; STAT5 phosphorylation and in vivo adoptive transfer proliferation assays

   PMID:19180469

   Open questions at the time

   • Relative contribution of cis versus trans presentation in physiological immune responses not quantified
   • Whether cis signaling activates distinct downstream programs versus trans signaling unknown
3. 2010 Medium

   Showing that DNA methylation regulates IL15RA expression — specifically that a CpG island controls alternative exon-skipping variants — identified an epigenetic mechanism for modulating receptor availability on immune cells.

   Evidence 5-azacitidine treatment of PBMCs with quantitative RT-PCR for transcript variants

   PMID:21097393

   Open questions at the time

   • Whether methylation-dependent regulation operates in non-immune tissues not tested
   • Functional consequences of individual splice variants not determined
   • No bisulfite sequencing of the CpG island provided
4. 2014 Medium

   Discovery of a non-canonical IL15RA signaling pathway (JAK1–STAT1/2–AKT–ERK, independent of IL-2Rβ/γc and STAT5) in triple-negative breast cancer cells revealed that IL15RA can drive autocrine pro-tumorigenic signaling in the absence of the conventional co-receptor chains.

   Evidence RNAi knockdown of IL15RA with phosphoprotein/western blot signaling analysis and co-culture paracrine assays in breast cancer cell lines

   PMID:24980552

   Open questions at the time

   • The molecular mechanism by which IL15RA engages JAK1 without IL-2Rβ/γc is unknown
   • Whether a distinct co-receptor substitutes for β/γc not investigated
   • Not independently replicated in other cancer types at that time
5. 2014 High

   Muscle-specific deletion of IL15RA established a cell-autonomous role for the receptor in restraining mitochondrial biogenesis and oxidative metabolism in skeletal muscle, distinct from its immune function.

   Evidence MCK-Cre conditional knockout mice; isometric contractile and fatigue assays; mitochondrial genome (COXII) quantification

   PMID:25505029

   Open questions at the time

   • Whether IL15RA acts through IL-15 binding or a ligand-independent mechanism in muscle not resolved
   • Downstream signaling pathway linking IL15RA to mitochondrial biogenesis in muscle not identified
6. 2017 High

   Two independent findings expanded IL15RA's tissue-autonomous functions: (1) IL15RA is required for osteoblast mineralization and RANKL/OPG-mediated osteoclast coupling in bone, and (2) IL-15Rα+ myeloid cells produce IGF-1 in response to IL-15, promoting tumor growth — linking the receptor to both skeletal homeostasis and the tumor microenvironment.

   Evidence Il15ra−/− mice with osteogenic cultures, ENPP1 activity assays, shRNA knockdown (bone); in vivo IL-15 injection with IGF-1 blocking in xenograft models (myeloid/tumor)

   PMID:28602725 PMID:29255466

   Open questions at the time

   • Mechanism by which IL15RA regulates ENPP1 activity in osteoblasts unknown
   • Whether the IGF-1 axis operates in immunocompetent hosts not fully established
   • Signaling pathway downstream of IL15RA in osteoblasts not identified
7. 2018 High

   Ultrastructural analysis of IL15RA-null muscle resolved that the increased mitochondrial capacity involves higher cristae density mediated by elevated OPA1 and cardiolipin, without fiber-type switching, establishing a role for IL15RA in regulating mitochondrial inner membrane architecture.

   Evidence Il15ra whole-body knockout; electron microscopy of subsarcolemmal and A-band mitochondria; OPA1 and cardiolipin quantification

   PMID:30301784

   Open questions at the time

   • Whether IL15RA directly or indirectly regulates OPA1 expression/processing is unknown
   • Mechanism linking IL15RA loss to cardiolipin accumulation not defined
8. 2020 Medium

   Demonstrating that IL-15 stimulation of IL15RA-expressing chondrocytes induces MMP-1 and MMP-3 release extended the receptor's non-immune functions to cartilage matrix remodeling.

   Evidence Ex vivo cartilage explant culture with IL-15; MMP release assays and immunohistochemistry

   PMID:32793194

   Open questions at the time

   • Downstream signaling pathway from IL15RA to MMP induction in chondrocytes not identified
   • Whether this contributes to osteoarthritis pathology in vivo not tested
9. 2024 Medium

   Identification of the IL15RA–STAT3–GPX4/ACSL3 axis in pancreatic cancer revealed that IL-15 from stellate cells confers ferroptosis resistance to tumor cells, adding STAT3 as another non-canonical downstream effector of IL15RA in cancer.

   Evidence Pancreatic stellate cell–cancer cell co-culture; in vitro and in vivo ferroptosis assays; STAT3 pathway and GPX4/ACSL3 expression analysis

   PMID:39396119

   Open questions at the time

   • Whether IL15RA engages STAT3 directly or through intermediate kinases not resolved
   • Generalizability to other cancer types not tested
10. 2025 Medium

    Upstream regulation of IL15RA was further defined: STAT1 transcriptionally activates the IL15RA promoter and METTL3-mediated m6A methylation stabilizes its mRNA; IL15RA then drives renal cell carcinoma metastasis via NF-κB/ZEB1, revealing a feedforward regulatory circuit.

    Evidence STAT1 promoter binding assay; m6A methylation analysis; NF-κB/ZEB1 metastasis assays in ccRCC cells

    PMID:41168330

    Open questions at the time

    • Direct ChIP-seq validation of STAT1 binding not fully detailed
    • Whether METTL3-mediated stabilization is specific to IL15RA or part of a broader program unknown
    • NF-κB/ZEB1 activation mechanism downstream of IL15RA not defined

• The mechanism by which IL15RA regulates mitochondrial ultrastructure (OPA1/cardiolipin) in muscle, the identity of a potential co-receptor enabling non-canonical signaling in cancer cells lacking IL-2Rβ/γc, and the structural basis for pathway-selective signaling (STAT5 versus STAT1/2 versus STAT3) across different cell contexts remain unresolved.
• No structural model of how IL15RA selects among JAK/STAT pathways in different cell types
• Ligand-independent functions of IL15RA in non-immune tissues not formally tested
• Whether muscle and bone phenotypes share a common downstream signaling mechanism is unknown